Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Cassava Sciences, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1998-01-01

Employees: 29

Market Cap: -

Website: http://www.cassavasciences.com

Clinical Trials

A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: Simufilam

First Posted Date: 2024-04-30

Last Posted Date: 2025-01-07

Lead Sponsor: Cassava Sciences, Inc.

Target Recruit Count: 27

Registration Number: NCT06390410

Locations: 🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects

Phase 1

Completed

Conditions: Absorption
Metabolism
Excretion

First Posted Date: 2024-01-08

Last Posted Date: 2025-03-20

Lead Sponsor: Cassava Sciences, Inc.

Target Recruit Count: 8

Registration Number: NCT06195319

Locations: 🇺🇸
Fortrea, Madison, Wisconsin, United States

Open-label Extension for Phase 3 Clinical Trials of Simufilam

Phase 3

Terminated

Conditions: Alzheimer Disease

Interventions: Drug: Simufilam

First Posted Date: 2022-10-12

Last Posted Date: 2025-05-23

Lead Sponsor: Cassava Sciences, Inc.

Target Recruit Count: 1081

Registration Number: NCT05575076

Locations: 🇺🇸
MDFirst Research, Chandler, Arizona, United States
🇺🇸
CCT Research - Gilbert Neurology Partners, Gilbert, Arizona, United States
🇺🇸
Xenoscience, Inc., Phoenix, Arizona, United States

and more 128 locations

Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

Phase 2

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: simufilam

First Posted Date: 2022-04-29

Last Posted Date: 2025-02-03

Lead Sponsor: Cassava Sciences, Inc.

Target Recruit Count: 90

Registration Number: NCT05352763

Locations: 🇺🇸
Cognitive Clinical Trials, Papillion, Nebraska, United States
🇺🇸
Valley Research Center, Inc., Imperial, California, United States
🇺🇸
Brain Matters Research, Delray Beach, Florida, United States

and more 7 locations

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Phase 3

Terminated

Conditions: Alzheimer Disease

Interventions: Drug: Placebo
Drug: Simufilam

First Posted Date: 2021-08-30

Last Posted Date: 2025-02-05

Lead Sponsor: Cassava Sciences, Inc.

Target Recruit Count: 1125

Registration Number: NCT05026177

Locations: 🇺🇸
Banner Alzheimer's Institute, Phoenix, Arizona, United States
🇺🇸
Arizona Neuroscience Research, LLC, Phoenix, Arizona, United States
🇺🇸
Clinical Endpoints, Scottsdale, Arizona, United States

and more 84 locations

Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

Phase 3

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Placebo
Drug: Simufilam

First Posted Date: 2021-08-06

Last Posted Date: 2025-05-25

Lead Sponsor: Cassava Sciences, Inc.

Target Recruit Count: 804

Registration Number: NCT04994483

Locations: 🇺🇸
MDFirst Research, Chandler, Arizona, United States
🇺🇸
CCT Research - Gilbert Neurology Partners, Gilbert, Arizona, United States
🇺🇸
Xenoscience, Inc., Phoenix, Arizona, United States

and more 84 locations

Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: simufilam

First Posted Date: 2021-06-21

Last Posted Date: 2023-08-22

Lead Sponsor: Cassava Sciences, Inc.

Target Recruit Count: 24

Registration Number: NCT04932655

Locations: 🇺🇸
Worldwide Clinical Trials Phase I Unit, San Antonio, Texas, United States

Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Simufilam 100 mg oral tablet
Drug: Placebo

First Posted Date: 2020-05-14

Last Posted Date: 2025-04-22

Lead Sponsor: Cassava Sciences, Inc.

Target Recruit Count: 220

Registration Number: NCT04388254

Locations: 🇺🇸
Cognitive Clinical Trials, Omaha, Nebraska, United States
🇺🇸
Sun Valley Research Center, Inc., Imperial, California, United States
🇺🇸
Brain Matters Research, Delray Beach, Florida, United States

and more 11 locations

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Simufilam 50 mg oral tablet
Drug: Placebo oral tablet
Drug: Simufilam 100 mg tablet

First Posted Date: 2019-09-06

Last Posted Date: 2021-09-29

Lead Sponsor: Cassava Sciences, Inc.

Target Recruit Count: 64

Registration Number: NCT04079803

Locations: 🇺🇸
Cognitive Clinical Trials, Omaha, Nebraska, United States
🇺🇸
Optimus U, Miami, Florida, United States
🇺🇸
IMIC, Inc., Palmetto Bay, Florida, United States

and more 2 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy